Reviva Pharmaceuticals Holdings, Inc. Share Price Nasdaq
Equities
TZAC
US76152G1004
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 42.99M 3.58B |
---|---|---|---|---|---|
Net income 2024 * | -37M -3.08B | Net income 2025 * | -43M -3.58B | EV / Sales 2024 * | - |
Net cash position 2024 * | 39.9M 3.32B | Net cash position 2025 * | 31.9M 2.66B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.24
x | P/E ratio 2025 * |
-1.17
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.29% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 11/20/11 | |
Narayan Prabhu
DFI | Director of Finance/CFO | 53 | 14/20/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 69 | 14/20/14 | |
Les Funtleyder
BRD | Director/Board Member | 55 | 14/20/14 |
Founder | 59 | 11/20/11 |
1st Jan change | Capi. | |
---|---|---|
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+46.90% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |